Latest News

FDA Accepts sNDA for Arcutis' Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date
FDA Accepts sNDA for Arcutis' Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date

November 29th 2023

The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.

RPT193 Demonstrates Greater Improvements in Clinical Efficacy Endpoints vs Placebo in Atopic Dermatitis
RPT193 Demonstrates Greater Improvements in Clinical Efficacy Endpoints vs Placebo in Atopic Dermatitis

November 28th 2023

AD Case Study: Topical Steroids Are Not Cutting It
AD Case Study: Topical Steroids Are Not Cutting It

November 28th 2023

Navigating the Complexities of Atopic Dermatitis
Navigating the Complexities of Atopic Dermatitis

November 25th 2023

Treatment With Rademikibart Led to Clinically Meaningful Responses in Patients With Atopic Dermatitis
Treatment With Rademikibart Led to Clinically Meaningful Responses in Patients With Atopic Dermatitis

November 22nd 2023

Latest CME Events & Activities

Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices

View More

Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings

View More

Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients

View More

Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

View More

20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Facing the Changing Landscape for Neuromodulators and Dermal Fillers

View More

Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis

View More

Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?

View More

"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation

View More

PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa

View More

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

© 2023 MJH Life Sciences

All rights reserved.